— The pharmaceutical company soared more than 10% after Cantor Fitzgerald reiterated an overweight rating on the stock. The firm said it sees sales of TG Therapeutics' treatment for relapsing forms of multiple sclerosis, Briumvi, to come in above expectations for the second quarter.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: